An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/2/2016
Start Date:March 2008
Contact:Harvey Pass, M.D.
Email:harvey.pass@med.nyu.edu
Phone:(212)731-5414

Use our guide to learn which trials are right for you!

A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma

Milataxel is a new taxane that may have several advantages over the currently available
taxanes. The current study is designed to determine the response rate of oral Milataxel in
patients with malignant Mesothelioma. The study specifically targets patients who have
recurring or progressive disease following previous chemotherapy.

This is a non-randomized, multicenter, open label, single agent phase II study. Patients
with malignant mesothelioma that has recurred or progressed following chemotherapy, and who
qualify for this study, will receive milataxel 60 mg/m2 orally on Day 1 of a 21 day cycle.
If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for
the second and subsequent cycles. Patients will receive drug for a total of six cycles.
Milataxel administration in excess of six cycles will be permitted at the discretion of the
Investigator if patients have stable or responding disease.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed malignant mesothelioma
for which they have received pemetrexed in combination with cisplatin as part of
chemotherapeutic regimen.

- Prior cancer therapy with pemetrexed/cisplatin must have been completed at least 30
days prior to the first cycle of milataxel; prior radiotherapy (less than 25% of the
bone marrow) must have been completed at least 30 days prior to study enrollment.

- Patients must have measurable disease by the Modified RECIST criteria

- Patients must have a life expectancy of at least 12 weeks and an ECOG performance
status of 0, 1 or 2

- Patients must be 18 years of age.

- Patients must have adequate organ and system function.

- Patients must be able to comply with the protocol treatments and procedures.

- Patients with known brain metastases may be included in the study, providing they are
clinically stable.

- Recovered from all acute toxicities caused by prior cancer therapies, except for
alopecia.

Exclusion Criteria:

- Patients must not have received any other chemotherapeutic treatment for malignant
mesothelioma other than pemetrexed and a platinum agent such as cisplatin.

- Patients with grade 2 or greater peripheral neuropathy.

- Prior cancer therapies not completed within 30 days prior to the first cycle of
milataxel; radiotherapy completed less than 30 days prior to study enrollment;
patients not recovered from radiation-related toxicities; patients receiving any
concurrent anti-cancer therapy, including trastuzumab, bevacizumab or an
investigational agent while on-study; patients with greater than 2 prior radiotherapy
treatments.

- Patients with known sensitivity to alcohol.

- Patients with significant intercurrent illnesses.

- Patients with symptomatic CNS metastases.

- Patients who have had major surgery within the past 14 days.

- Patients who require or are likely to require any strong modifier of CYP450 activity
to be taken prior to milataxel administration

- Patients who are receiving high dose steroids (more than a dexamethasone-equivalent
dose of 4 mg per day).

- Patients with malabsorption syndrome, disease significantly affecting
gastrointestinal function, or major resection of the stomach or small bowel that
could affect absorption of the study drug.

- Women who are pregnant or breastfeeding.
We found this trial at
3
sites
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
New York, New York 10016
?
mi
from
New York, NY
Click here to add this to my saved trials